Journal September 19, 2026 6 min read

How to verify Selank purity and batch documentation

A laboratory-focused guide to verifying Selank purity and batch documentation, covering the formal identifiers, analytical methods, and the limits of the published evidence base.

peptides-pro Editorial

Selank is the research name for a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), also written as TP-7 or Selanc. It is a synthetic analogue of the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended at the C-terminus by a Pro-Gly-Pro tripeptide to resist enzymatic degradation. Its molecular formula is C33H57N11O9 and its monoisotopic molecular mass is approximately 751.4 Da; the free base is commonly supplied as a lyophilised acetate salt. The compound is a research chemical and is not approved for human use in any jurisdiction. The published work on this molecule centres on its interaction with the GABAergic system and on modulation of enkephalin degradation, with a secondary literature on cytokine and monoamine signalling.

Verifying purity and batch documentation for a peptide like Selank is a matter of matching three independent records: the certificate of analysis (CoA) supplied with the lot, the analytical data behind the numbers on that certificate, and the identity of the material against the sequence above. A CoA that reports a single purity figure without the chromatogram, the method, and the column and gradient conditions is not verifiable. The sections below set out what the published literature does and does not establish about this compound, followed by the documentation checks a laboratory can apply to any lot.

Research Studies

Selank and GABAergic signalling in rodent models

The most frequently cited mechanism for Selank is an effect on the GABA-A receptor complex. In rodent studies, the peptide has been reported to modulate GABA-A receptor expression and to produce anxiolytic-like behaviour in standard conflict and open-field paradigms. These findings are animal-only. No controlled human trial of Selank has been identified in the evidence reviewed for this page, and the behavioural endpoints used in the rodent work (thigmotaxis, punished responding) do not map directly onto any human clinical endpoint. A laboratory citing this literature should describe it as preclinical.

Selank and enkephalin degradation in vitro

In vitro work has examined the effect of Selank on enkephalin-degrading enzymes, with the C-terminal Pro-Gly-Pro extension proposed to interfere with peptidase recognition. This is an in vitro observation using enzyme preparations and synthetic substrates. It does not establish that the same inhibition occurs at any particular concentration in vivo, and it does not establish a dose. The relevance of the finding to any intact system is a hypothesis, not a result.

Selank and cytokine expression in animal models

Rodent and ex vivo studies have reported changes in interleukin and interferon expression following Selank administration. The direction and magnitude of these changes vary between models, and the studies are small. This literature is animal-only and should be treated as hypothesis-generating. It does not support any claim about immune function in humans.

Selank and monoamine turnover in rodent brain tissue

Several rodent studies have measured serotonin and dopamine metabolite concentrations in brain tissue after Selank administration. The reported effects are modest and inconsistent across brain regions. These are animal-only findings from tissue homogenate measurements, and they do not translate into a statement about neurotransmitter levels in living humans.

Selank and cognitive endpoints in animal models

Rodent studies using passive avoidance and maze tasks have reported effects of Selank on retention and acquisition. The models are animal-only, the sample sizes are small, and the tasks are sensitive to non-cognitive confounds such as locomotor activity and shock sensitivity. No human cognitive endpoint has been reported for this compound in the evidence reviewed here.

Selank and stability in biological matrices

Analytical studies have examined the stability of Selank in plasma and buffer, generally finding rapid degradation unless the Pro-Gly-Pro extension is present. These are in vitro measurements. They are relevant to how a laboratory designs a pharmacokinetic assay, not to any clinical claim.

Selank and batch documentation: what a CoA should contain

A verifiable CoA for a research peptide should report, at minimum, the lot number, the date of analysis, the method used for each test, and the acceptance criteria. For Selank specifically, the following table summarises the tests a laboratory should expect to see and the method that should be named for each.

Test	Method that should be named	What it establishes
Identity	ESI-MS or MALDI-TOF	Observed mass matches the theoretical mass of the sequence
Purity	RP-HPLC with UV detection at 214 nm	Percentage of total peak area attributable to the main peak
Peptide content	Elemental analysis or amino acid analysis	Mass of peptide versus mass of counter-ion and water
Counter-ion	Ion chromatography or NMR	Acetate or trifluoroacetate content
Water content	Karl Fischer titration	Residual moisture in the lyophilised powder
Appearance	Visual inspection	Colour and form of the powder

A purity figure without the chromatogram is not verifiable. The chromatogram should show the baseline, the main peak, and any impurity peaks, and the integration method should be stated. A laboratory receiving a CoA that reports only a percentage should request the underlying data before accepting the lot.

Selank and the limits of the published evidence

The evidence base for Selank is small, preclinical, and concentrated in a limited number of research groups. The studies reviewed here are animal-only or in vitro. There is no controlled human trial in the evidence reviewed for this page. A laboratory writing about this compound should state that plainly rather than implying a clinical literature that does not exist. The absence of human data is not a finding about safety or efficacy; it is an absence of data.

Selank and comparison with related peptides

Selank is frequently discussed alongside tuftsin, its parent tetrapeptide, and Semax, a related synthetic peptide. The table below compares the three on the identifiers that matter for documentation.

Compound	Sequence	Approximate mass	Relationship
Tuftsin	Thr-Lys-Pro-Arg	500.6 Da	Endogenous parent tetrapeptide
Selank	Thr-Lys-Pro-Arg-Pro-Gly-Pro	751.4 Da	Synthetic analogue with C-terminal Pro-Gly-Pro extension
Semax	Met-Glu-His-Phe-Pro-Gly-Pro	813.9 Da	Unrelated synthetic peptide sharing the Pro-Gly-Pro extension

The shared Pro-Gly-Pro extension is the feature most often invoked to explain stability, and it is the feature a laboratory should confirm by mass spectrometry. A lot that returns the correct mass for the full sequence is consistent with the intended product; a lot that returns the mass of the tetrapeptide alone is not.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is a recommendation for human use.